MedPath

Splanchnic Venous Capacitance in Postural Tachycardia Syndrome

Phase 2
Recruiting
Conditions
Postural Tachycardia Syndrome (POTS)
Registration Number
NCT05375968
Lead Sponsor
Vanderbilt University Medical Center
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
All
Target Recruitment
50
Inclusion Criteria

Inclusion Criteria:<br><br> - Between 18 and 50years of age<br><br> - Cases: Diagnosis of POTS with presyncope symptoms after meals Or<br><br>Controls:<br><br> - With no significant past medical history, non-smokers and not on chronic<br> medications.<br><br> - Body mass index (BMI) between 18.5 to 29.9 kg/m2<br><br> - If pre-menopausal women: must have regular menstrual cycle.<br><br>Exclusion Criteria:<br><br> - BMI above =30 kg/m2<br><br> - Irregular menstrual cycle<br><br> - Intolerance to CPAP.<br><br> - Chronic use of acetaminophen<br><br> - Heart problems: myocardial infarction, angina, heart failure, stroke<br><br> - Undergone any heart related procedures or stents or on pacemaker.<br><br> - Uncontrolled hypertension.<br><br> - Type 1 or type 2 diabetes mellitus<br><br> - Pregnant or breast-feeding women.<br><br> - Impaired liver function<br><br> - Impaired Kidney function test.<br><br> - Anemia (Hematocrit<34%).<br><br> - Ongoing substance abuse.<br><br> - Subjects with abnormal EKG<br><br> - History of seizures.<br><br> - Diagnosed with neuropathy due to any reason<br><br> - History of neck surgery.<br><br> - Smoker,<br><br> - On statin therapy for high cholesterol<br><br> - Rheumatoid arthritis.<br><br> - On oral corticosteroids,<br><br> - Current infections<br><br> - Documented of moderate decrease in blood volume

Exclusion Criteria

Not provided

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Change in splanchnic venous capacitance in Postural Orthostatic Tachycardia Syndrome;Effect of glucose-induced GIP secretion on splanchnic venous capacitance;Effect of glucose-induced GIP secretion on POTS postprandial symptoms.
Secondary Outcome Measures
NameTimeMethod
Measure Glucose-dependent Insulinotropic polypeptide (GIP) hormone level in POTS patients and Controls after 75 grams of glucose ingestion
© Copyright 2025. All Rights Reserved by MedPath